BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

Regulatory News:

BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, announces that it held its Shareholders’ meeting at its headquarters on April 8, 2014 and has adopted all the resolutions recommended by its Board of Directors.

Among other decisions, the Shareholders’ meeting has confirmed the Director’s mandate for annual re-election of:

• Judith Greciet, CEO of BioAlliance Pharma
• David Solomon, independant Board member
• Financière de la Montagne, represented by Nicolas Trebouta

These mandates have been renewed for an additional 3-year period, expiring at the Shareholders’s Meeting of 2017.

"With these renewals, the Shareholders have confirmed their confidence in the Board Members to pursue their mission alongside BioAlliance’s Management, to further develop the Company and face up to its growth challenge,” comments Patrick Langlois, Chairman of the Board of Directors.

As of today, BioAlliance Pharma’s Board of Directors is composed of:

• Patrick Langlois, Chairman of the Board of Directors and independent Board Member
• Judith Greciet, Chief Executive Officer and Board Member
• Russell Greig, independent Board Member
• Danièle Guyot-Caparros, independent Board Member
• Thomas Hofstaetter, independent Board Member
• David H. Solomon, independent Board Member
• Financière de la Montagne, represented by Nicolas Trebouta, Board Member
• Kurma Life Sciences Partners, represented by Rémi Droller, Board Member

Voting results of the Combined Shareholders Meeting are available on our website at www.bioalliancepharma.com, section Investors/Shareholders’ meeting.

About BioAlliance Pharma

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products

Livatag^® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going

Validive^® (Clonidine Lauriad^®) (mucositis): Phase II on going

AMEP^® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website ().